All
7 October 2020
Federation Bio Launches with $50 Million Series A Financing and Expands Team to Pioneer Diverse Microbial Therapies
Federation Bio, a microbial therapeutics company targeting diseases in which the human microbiome can play a curative role, today announced that it has closed a $50 million...
29 September 2020
LARQ, leading health and wellness hydration brand, announced today a round closure of $10 million in Series A funding
LARQ was started with a simple vision where innovative technology can be combined with inspirational design to help people access pristine drinking water easily and...
25 September 2020
Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline
Galecto., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today the successful completion of a $64...
23 September 2020
Enterome announces first patient dosed in Phase 2a trial of sibofimloc in Crohn’s disease
ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, today...
22 September 2020
Siolta Therapeutics Raises $30M Series B for the Prevention and Treatment of Allergic Diseases
Siolta’s live biotherapeutic product (LBP) platform is designed to develop microbiome-based medicines and diagnostics for the prevention and treatment of chronic diseases in...
18 September 2020
Microbiotica Wins Young Company of the Year at Business Weekly Awards
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, has been named Business Weekly Young Company of the Year 2020. The “Young Company of the...
17 September 2020
The Medical University of Pleven Leads the Digital Transformation of Medical Education in Bulgaria with Lecturio
Already an attractive destination for international and domestic medical students alike, the Medical University of Pleven now joins with Lecturio's help over 100 other medical...
9 September 2020
LNC Therapeutics Receives FDA Investigational New Drug Approval to Initiate a Phase 1 Clinical Trial on Xla1 for the Treatment of Obesity and Metabolic Diseases
LNC Therapeutics, a French biotech company harnessing the properties of keystone single-strain bacteria to develop ground-breaking microbiome-based drugs, today announced that...
9 September 2020
Enterome – First Patient Dosed in a Phase 1/2 Trial with EO2401, an Innovative ‘OncoMimic’ based Immunotherapy Candidate Targeting Adrenal Tumors
ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, today...